MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
77.01
+2.53
+3.40%
Pre Market: 77.94 +0.93 +1.21% 04:01 03/17 EDT
OPEN
77.83
PREV CLOSE
74.48
HIGH
78.23
LOW
76.00
VOLUME
3
TURNOVER
0
52 WEEK HIGH
113.51
52 WEEK LOW
61.80
MARKET CAP
5.51B
P/E (TTM)
-19.6129
1D
5D
1M
3M
1Y
5Y
1D
Nuvalent Price Target Maintained With a $100.00/Share by UBS
Dow Jones · 2d ago
Nuvalent Raised to Buy From Neutral by UBS
Dow Jones · 2d ago
UBS Upgrades Nuvalent to Buy, Maintains Price Target to $100
Benzinga · 2d ago
Weekly Report: what happened at NUVL last week (0303-0307)?
Weekly Report · 6d ago
Nuvalent’s Promising Oncology Position and Strategic Differentiation Justify Buy Rating
TipRanks · 03/03 20:35
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Simply Wall St · 03/03 14:22
Nuvalent’s Strategic Expansion and Clinical Progress Drive Buy Rating
TipRanks · 03/03 11:17
Weekly Report: what happened at NUVL last week (0224-0228)?
Weekly Report · 03/03 09:09
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.